IP Library Granted Patent US 8,957,109
Granted Patent B2
US 8,957,109 · App. 13/891,975 · Granted Feb 17, 2015

Chroman derivatives, medicaments and use in therapy

Inventors: Andrew Heaton (Abbotsford, AU); Alan Husband (McMahon's Point, AU)
Assignee: MEI Pharma, Inc.
C07D311/58C07D311/62A23L1/3002C07D311/38A61K31/282A61K31/337A61K31/353A61K31/655A61K31/7068A61K33/24A61K41/0038
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,957,109
App. No.
13/891,975
Granted
Feb 17, 2015
Kind
B2
Abstract

Chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Claims (39)

1. A method of treating cancer, the method comprising administering to a subject in need thereof a compound of the formula (I-a):

wherein

R 1 is hydrogen;

R 2 and R 3 are independently hydrogen, hydroxy, C 1-6 alkoxy, halo or C 1-6 alkyl, with the exception that R 2 and R 3 are not both hydrogen; and

R 4 , R 5 and R 6 are independently hydrogen, hydroxy, C 1-6 alkoxy, or C 1-6 alkyl;

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein R 2 is C 1-6 alkoxy or hydroxy.

3. The method of claim 1 , wherein R 2 is methoxy or hydroxy.

4. The method of claim 1 , wherein R 3 hydrogen.

5. The method of claim 1 , wherein R 4 is C 1-6 alkoxy or hydroxy.

6. The method of claim 1 , wherein R 4 is methoxy or hydroxy.

7. The method of claim 1 , wherein

R 2 is methoxy or hydroxy;

R 3 is hydrogen;

R 4 is methoxy or hydroxy; and

R 5 and R 6 are hydrogen;

or a pharmaceutically acceptable salt thereof.

8. The method of claim 7 , wherein the compound has the structure:

9. The method of claim 1 , wherein the cancer is of epithelial, mesenchymal, or neural origin.

10. The method of claim 9 , wherein the cancer is ovarian cancer, breast cancer, pancreatic cancer, or melanoma.

11. The method of claim 1 , wherein administering the compound of formula (I-a) results in the cancer being sensitized to one or more chemotherapeutic agent or radiotherapy, and the method further comprises administering to the subject a chemotherapeutic agent or radiotherapy to which the cancer has been sensitized.

12. The method of claim 11 , wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, paclitaxel, gemcitabine, doxorubicin, decarbazine, or topotecan.

13. A method of sensitizing a cancer cell, the method comprising contacting the cancer cell with a compound of formula (I-a):

wherein

R 1 is hydrogen;

R 2 and R 3 are independently hydrogen, hydroxy, C 1-6 alkoxy, halo or C 1-6 alkyl, with the exception that R 2 and R 3 are not both hydrogen; and

R 4 , R 5 and R 6 are independently hydrogen, hydroxy, C 1-6 alkoxy, or C 1-6 alkyl;

or a pharmaceutically acceptable salt thereof.

14. The method of claim 13 , wherein

R 2 is methoxy or hydroxy;

R 3 is hydrogen;

R 4 is methoxy or hydroxy; and

R 5 and R 6 are hydrogen;

or a pharmaceutically acceptable salt thereof.

15. The method of claim 14 , wherein the compound has the structure:

16. The method of claim 13 , wherein the cancer is of epithelial, mesenchymal, or neural origin.

17. The method of claim 16 , wherein the cancer is ovarian cancer, breast cancer, pancreatic cancer, or melanoma.

18. The method of claim of 13 , wherein the method of sensitizing comprises sensitizing the cancer cell to a chemotherapeutic agent to which, prior to the method of sensitizing, the cancer cell is not sensitive or is poorly sensitive.

19. The method of claim 13 , wherein the method of sensitizing comprises sensitizing the cancer cell to radiotherapy to which, prior to the method of sensitizing, the cancer cell is not sensitive or is poorly sensitive.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2014
From: HEATON, ANDREW; HUSBAND, ALAN
To: NOVOGEN RESEARCH PTY LTD
Reel/Frame 033623/0217 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2014
From: NOVOGEN LIMITED AND/OR NOVOGEN RESEARCH PTY LIMITED
To: MARSHALL EDWARDS, INC.
Reel/Frame 033623/0265 →
CHANGE OF NAME Recorded Aug 27, 2014
From: MARSHALL EDWARDS, INC.
To: MEI PHARMA, INC.
Reel/Frame 033623/0350 →
Priority Claims (3)
JP 2004/315009 · Oct 29, 2004 · national
AU 2004/906363 · Nov 5, 2004 · national
WO PCT/AU2004/001619 · Nov 19, 2004 · international
Continuity (6)
Continuation 13415697 · Mar 8, 2012
Continuation 13231794 · Sep 13, 2011
Division 11230505 · Sep 21, 2005
Provisional Application 60611299 · Sep 21, 2004
Provisional Application 60676934 · May 3, 2005
Related Publication 20140161908A1 · Jun 12, 2014